| Patient | Mahalia Jackson |
|---|---|
| Date of birth | 1911-10-26 |
| Identifiers | MRN HR-ML035-SYN-TD; SSN (made up) 000-35-4692 |
| Document date | 1964-02-23 |
| Author | Beatrice Fontenot, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
EBUS result and pulmonology consultation. [S]
Ms. Jackson returns two weeks after her first visit. The CT of the chest two days after that visit showed enlarged hilar and mediastinal lymph nodes and small nodules along the airways in both upper lobes. EBUS-guided needle aspiration five days ago found non-necrotizing granulomas in three lymph node stations, with negative stains for mycobacteria and fungi; cultures are growing nothing so far. The interferon-gamma release assay and HIV test from the first visit were negative. She stopped the over-the-counter calcium and vitamin D tablets as advised. Her breathlessness and cough are unchanged, and she had one more spell of palpitations while singing at church. She has postponed her concerts for the next three weeks. Dr. Asante-Miller saw her this morning, and she had full lung function tests. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Tissue | Non-necrotizing granulomas at stations 4R, 7 and 11L; stains negative; cultures pending; lavage lymphocytes 32 percent, CD4 to CD8 ratio 5.2 |
| Infection excluded so far | Interferon-gamma release assay and HIV negative; acid-fast and fungal stains negative |
| Lung function | FVC 74 percent and DLCO 62 percent of predicted |
| Symptoms | Breathlessness and cough unchanged; one more spell of palpitations |
| Work | Concerts postponed for three weeks |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever, night sweats or weight loss |
| Respiratory | Positive | Breathless on one flight of stairs; dry cough |
| Cardiovascular | Positive | One spell of palpitations with light-headedness; no chest pain or fainting |
| Eyes | Negative | No redness, pain or blurred vision |
| Integumentary | Negative | No rash, nodules or plaques |
| Psychiatric | Positive | Anxious about singing again; PHQ-9 6; no thoughts of self-harm |
6 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1964-02-23 | Body height | 170 | cm | S |
| 1964-02-23 | Body weight | 91.6 | kg | S |
| 1964-02-23 | Body mass index (BMI) [Ratio] | 31.7 | kg/m2 | S |
| 1964-02-23 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1964-02-23 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1964-02-23 | Heart rate | 82 | /min | S |
| 1964-02-23 | Respiratory rate | 18 | /min | S |
| 1964-02-23 | Body temperature | 36.7 | Cel | S |
| 1964-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1964-02-23 | FVC measured/predicted | 74 | % | >=80% | Low | S |
| 1964-02-23 | FEV1 measured/predicted | 76 | % | >=80% | Low | S |
| 1964-02-23 | FEV1/FVC | 80 | % | >=70% | Normal | S |
| 1964-02-23 | Diffusion capacity.carbon monoxide/Predicted | 62 | % | >=80% | Low | S |
| 1964-02-23 | Calcium [Mass/volume] in Serum or Plasma | 10.7 | mg/dL | 8.6-10.3 mg/dL | High | S |
| 1964-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 65 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 1964-02-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 91.6 kg; blood pressure 126/78, pulse 82 and irregular with ectopic beats; oxygen saturation 95 percent |
| Respiratory | Clear to auscultation; no crackles |
| Cardiovascular | Occasional ectopic beats; no murmur; no ankle swelling |
| Skin | No erythema nodosum, plaques or scar infiltration |
| Lymph nodes | No palpable cervical, axillary or inguinal nodes |
| Psychiatric | Warm, direct, worried |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation. |
| Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | active | confirmed | R00.2 | S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed. |
| Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | active | confirmed | E83.52 | S — Synthetic finding; resolved on treatment. |
| Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | D86.2 | S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis | Once, when the diagnosis is uncertain from the clinical picture | Up to date | EBUS-guided needle aspiration rather than mediastinoscopy: non-necrotizing granulomas at three stations; no malignant cells |
| Laboratory | Exclusion of other granulomatous causes | At diagnosis | Ordered | Acid-fast and fungal stains negative; mycobacterial and fungal cultures pending, final in six to eight weeks; interferon-gamma release assay and HIV negative from the first visit |
| Imaging | Spirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO) | At diagnosis, three months after starting treatment, then every three to six months while treatment changes | Completed today | FVC 74 percent, FEV1 76 percent, FEV1/FVC 80 percent, DLCO 62 percent of predicted: mild restriction with reduced gas transfer |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 10.7 mg/dL off the supplement |
| Laboratory | Kidney function | At diagnosis, then with calcium checks | Completed today | Creatinine 1.04 mg/dL, eGFR 65 |
| Laboratory | 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D | At diagnosis, and before any vitamin D replacement | Up to date | From the first visit: 25-hydroxyvitamin D 22 ng/mL (low) and 1,25-dihydroxyvitamin D 84 pg/mL (high), so vitamin D is not to be given while calcium is high |
| Laboratory | Liver tests, alkaline phosphatase and blood count | At diagnosis | Up to date | From the first visit: alkaline phosphatase 128 U/L, ALT 28 U/L; lymphocytes 0.9; to be followed on treatment |
| Examination | Baseline ECG | At diagnosis for every patient | Up to date | First visit: first-degree atrioventricular block and frequent ventricular ectopy |
| Examination | Holter monitoring | When the ECG is abnormal or there are palpitations | Ordered | Tomorrow |
| Imaging | Echocardiogram | When cardiac involvement is suspected | Ordered | This week |
| Imaging | Cardiac MRI with late gadolinium enhancement | When cardiac involvement is suspected | Ordered | Within two weeks |
| Imaging | Cardiac FDG-PET | When cardiac involvement is suspected, before glucocorticoids | Ordered | Within two weeks, after a 72-hour high-fat, very-low-carbohydrate diet |
| Examination | Eye examination | At diagnosis for every patient, then yearly | Ordered | Ophthalmology appointment next week |
| Laboratory | Hepatitis B and C screening | Before immunosuppressive treatment | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody drawn today |
| Laboratory | Serum angiotensin-converting enzyme | Not used for diagnosis | Not indicated | Not drawn: its sensitivity and specificity are too low to confirm or exclude sarcoidosis, and the diagnosis rests on tissue |
| Referral | Pulmonology (sarcoidosis) | At diagnosis | Completed today | Seen this morning; recommendations in the consultation note |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 6 |
Goal progress:
Guideline basis: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Baughman RP, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc 2016;13(8):1244-1252 (PMID 27509154) (2016); Mirsaeidi M, et al. Racial difference in sarcoidosis mortality in the United States. Chest 2015;147(2):438-449 (PMID 25188873) (2015); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Holter, echocardiogram, eye examination, cardiac MRI and FDG-PET within two weeks; review in two weeks to decide treatment. Call 911 for fainting, chest pain or a sustained racing heart. Next scheduled visit 1964-03-09: cardiac MRI and FDG-PET results: cardiac sarcoidosis; start of prednisone and methotrexate, bone and infection protection, and electrophysiology referral. [S]